170 related articles for article (PubMed ID: 25129204)
1. Serum suPAR levels are modulated by immunosuppressive therapy of minimal change nephrotic syndrome.
Gellermann J; Schaefer F; Querfeld U
Pediatr Nephrol; 2014 Dec; 29(12):2411-4. PubMed ID: 25129204
[TBL] [Abstract][Full Text] [Related]
2. The clinical pattern of nephrotic syndrome in children has no effect on the concentration of soluble urokinase receptor (suPAR) in serum and urine.
Ochocińska A; Jarmużek W; Janas R
Pol Merkur Lekarski; 2018 Apr; 44(262):183-187. PubMed ID: 29775445
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome.
Gellermann J; Weber L; Pape L; Tönshoff B; Hoyer P; Querfeld U;
J Am Soc Nephrol; 2013 Oct; 24(10):1689-97. PubMed ID: 23813218
[TBL] [Abstract][Full Text] [Related]
4. Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children.
Sinha A; Bajpai J; Saini S; Bhatia D; Gupta A; Puraswani M; Dinda AK; Agarwal SK; Sopory S; Pandey RM; Hari P; Bagga A
Kidney Int; 2014 Mar; 85(3):649-58. PubMed ID: 24429405
[TBL] [Abstract][Full Text] [Related]
5. Steroid resistant focal segmental glomerulosclerosis: effect of arterial hyalinosis on outcome: single center study.
Soliman AR; Maamoun H; Soliman H; Ahmed RM
Rom J Intern Med; 2021 Jun; 59(2):127-133. PubMed ID: 33565308
[No Abstract] [Full Text] [Related]
6. Long-term outcome of Japanese children with complicated minimal change nephrotic syndrome treated with mycophenolate mofetil after cyclosporine.
Fujinaga S; Hirano D; Nishino T; Umeda C; Watanabe Y; Nakagawa M
Pediatr Nephrol; 2019 Nov; 34(11):2417-2421. PubMed ID: 31435725
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome.
Dorresteijn EM; Kist-van Holthe JE; Levtchenko EN; Nauta J; Hop WC; van der Heijden AJ
Pediatr Nephrol; 2008 Nov; 23(11):2013-20. PubMed ID: 18622632
[TBL] [Abstract][Full Text] [Related]
8. Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil.
Gellermann J; Querfeld U
Pediatr Nephrol; 2004 Jan; 19(1):101-4. PubMed ID: 14753204
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate mofetil in treatment of childhood steroid-resistant nephrotic syndrome.
Gargah TT; Lakhoua MR
J Nephrol; 2011; 24(2):203-7. PubMed ID: 21319130
[TBL] [Abstract][Full Text] [Related]
10. Circulating suPAR in two cohorts of primary FSGS.
Wei C; Trachtman H; Li J; Dong C; Friedman AL; Gassman JJ; McMahan JL; Radeva M; Heil KM; Trautmann A; Anarat A; Emre S; Ghiggeri GM; Ozaltin F; Haffner D; Gipson DS; Kaskel F; Fischer DC; Schaefer F; Reiser J;
J Am Soc Nephrol; 2012 Dec; 23(12):2051-9. PubMed ID: 23138488
[TBL] [Abstract][Full Text] [Related]
11. Relationship between serum soluble urokinase plasminogen activator receptor level and steroid responsiveness in FSGS.
Li F; Zheng C; Zhong Y; Zeng C; Xu F; Yin R; Jiang Q; Zhou M; Liu Z
Clin J Am Soc Nephrol; 2014 Nov; 9(11):1903-11. PubMed ID: 25318750
[TBL] [Abstract][Full Text] [Related]
12. The impact of mycophenolate mofetil versus azathioprine as adjunctive therapy to cyclosporine on the rates of renal allograft loss due to glomerular disease recurrence.
Pham PT; Pham PC
Nephrol Dial Transplant; 2012 Jul; 27(7):2965-71. PubMed ID: 22207327
[TBL] [Abstract][Full Text] [Related]
13. Decreased glomerular filtration as the primary factor of elevated circulating suPAR levels in focal segmental glomerulosclerosis.
Harita Y; Ishizuka K; Tanego A; Sugawara N; Chikamoto H; Akioka Y; Tsurumi H; Miura K; Gotoh Y; Tsujita M; Yamamoto T; Horike K; Takeda A; Oka A; Igarashi T; Hattori M
Pediatr Nephrol; 2014 Sep; 29(9):1553-60. PubMed ID: 24705794
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil therapy for childhood-onset steroid dependent nephrotic syndrome after long-term cyclosporine: extended experience in a single center.
Fujinaga S; Ohtomo Y; Hirano D; Nishizaki N; Someya T; Ohtsuka Y; Kaneko K; Shimizu T
Clin Nephrol; 2009 Oct; 72(4):268-73. PubMed ID: 19825332
[TBL] [Abstract][Full Text] [Related]
15. Circulating suPAR as a biomarker of disease severity in children with proteinuric glomerulonephritis.
Sołtysiak J; Zachwieja J; Benedyk A; Lewandowska-Stachowiak M; Nowicki M; Ostalska-Nowicka D
Minerva Pediatr; 2019 Feb; 71(1):4-11. PubMed ID: 27070416
[TBL] [Abstract][Full Text] [Related]
16. Sequential maintenance therapy with cyclosporin A and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome.
Gellermann J; Ehrich JH; Querfeld U
Nephrol Dial Transplant; 2012 May; 27(5):1970-8. PubMed ID: 21976740
[TBL] [Abstract][Full Text] [Related]
17. CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance.
Cara-Fuentes G; Wei C; Segarra A; Ishimoto T; Rivard C; Johnson RJ; Reiser J; Garin EH
Pediatr Nephrol; 2014 Aug; 29(8):1363-71. PubMed ID: 24263531
[TBL] [Abstract][Full Text] [Related]
18. Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome.
Mendizábal S; Zamora I; Berbel O; Sanahuja MJ; Fuentes J; Simon J
Pediatr Nephrol; 2005 Jul; 20(7):914-9. PubMed ID: 15891923
[TBL] [Abstract][Full Text] [Related]
19. [Mycophenolate mofetil in treatment of childhood nephrotic syndrome--preliminary report].
Kwinta-Rybicka J; Wilkosz K; Wierzchowska-Słowiacze EK; Ogarek I; Moczulska A; Stec Z; Pełkowska A; Sancewicz-Pach K; Pietrzyk JA
Przegl Lek; 2006; 63 Suppl 3():44-8. PubMed ID: 16898486
[TBL] [Abstract][Full Text] [Related]
20. A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease.
Wada T; Nangaku M; Maruyama S; Imai E; Shoji K; Kato S; Endo T; Muso E; Kamata K; Yokoyama H; Fujimoto K; Obata Y; Nishino T; Kato H; Uchida S; Sasatomi Y; Saito T; Matsuo S
Kidney Int; 2014 Mar; 85(3):641-8. PubMed ID: 24429394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
